47 results on '"Saiag, Philippe"'
Search Results
2. Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study
3. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.
4. Extra-cranial radiotherapy in anti-PD-1-treated melanoma patients: A systematic review
5. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023
6. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023
7. Distinct Regulation of EZH2 and its Repressive H3K27me3 Mark in Polyomavirus-Positive and -Negative Merkel Cell Carcinoma
8. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial
9. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
10. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma
11. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
12. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
13. Narrow resection margins are not associated with mortality or recurrence in patients with Merkel cell carcinoma: A retrospective study
14. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
15. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
16. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
17. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns
18. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
19. Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?
20. Impact of adjuvant radiation therapy on survival and recurrence in patients with stage I-III Merkel cell carcinoma: A retrospective study of 312 patients
21. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012
22. MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in Southern European populations: Results from a Meta-analysis
23. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis
24. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas
25. Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma
26. Différentiel d’efficacité de l’immunothérapie selon le profil d’exposition solaire du site de survenue du mélanome primitif : étude de cohorte prospective multicentrique MELBASE
27. Gastrites immuno-induites : incidence, caractéristiques et prise en charge
28. Impact du confinement lié au COVID-19 sur le retard au diagnostic et la sévérité du mélanome
29. Risque de toxicité immunomédiée chez les patients avec antécédents d’auto-immunité traités par inhibiteurs de checkpoint pour un mélanome métastatique
30. La radiothérapie adjuvante est associée à une diminution du risque de mortalité et de récidive dans le traitement initial du carcinome de Merkel stades I-III : étude rétrospective muticentrique
31. Les inhibiteurs de checkpoint immunitaires sont associés à une amélioration de la survie chez des patients atteints de carcinome de Merkel avancé ou métastatique : résultats d’une cohorte en vie réelle de 98 patients
32. EZH2, une cible thérapeutique potentielle pour le carcinome à cellules de Merkel
33. L’investigation de l’axe RB1-SOX2 constitue un outil pour le diagnostic et la détermination du statut viral des carcinomes à cellules de Merkel
34. Étude d’un algorithme adapté de gestion de la fièvre chez les patients traités par dabrafénib + tramétinib en adjuvant : premiers résultats de la cohorte française de COMBI-APlus
35. Résultats finaux d’une cohorte de 705 patients atteints de mélanome avancé et ayant débuté un traitement par pembrolizumab au cours de son programme français d’ATU
36. Myocardites sous inhibiteurs de points de contrôle immunitaires (ICI)
37. Technique originale de réparation d’une perte de substance non transfixiante de l’aile narinaire
38. Efficacité de la radiothérapie (RT) hypofractionnée au cours du mélanome avancé traité par monothérapie anti-PD-1
39. Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca
40. A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients
41. Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies
42. Nivolumab to control molecular response in chronic myeloid leukemia
43. Une complication rare d’un tatouage permanent
44. Chirurgie micrographique (CM) : le meilleur traitement des carcinomes basocellulaires (CBC) de mauvais pronostic
45. Routine ultrasonography in melanoma follow-up?
46. Ont collaboré à cet ouvrage
47. Failure of warfarin in treatment of calcinosis universalis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.